Evommune, Inc. Revenue
Evommune, Inc. (EVMN) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $10.00M.
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $13.00M, a 85.71% increase from fiscal 2024.
- Evommune, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $10.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $10.00M derived: sum of 3 quarters · filed 2026-05-07 | $10.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.00M derived: sum of 2 quarters · filed 2026-03-05 | $10.00M derived: sum of 3 quarters · filed 2026-08-06 | $13.00M 10-K · filed 2026-03-05 |
| 2025-09-30 | $10.00M 10-Q · filed 2025-12-11 | $10.00M derived: sum of 2 quarters · filed 2026-08-06 | $13.00M 10-Q · filed 2025-12-11 | $13.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $3.00M 10-Q · filed 2026-08-06 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-07 | $3.00M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.00M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $7.00M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |